Effectiveness and Safety of a Mushroom Supplement for Fatigue: A Trial in the Making
Bottom line: A 6-week trial may suggest that a lingzhi mushroom supplement is associated with improvements in chronic fatigue and post-COVID-19 fatigue symptoms.
A study in Hong Kong is about to test whether a traditional mushroom supplement can help people suffering from chronic fatigue — the kind that lingers even after sleep and rest. Chronic fatigue syndrome is a condition that leaves people exhausted with no clear cause or treatment. Now, researchers are investigating whether a supplement made from Ganoderma lucidum, also known as lingzhi, might offer relief.

The Mushroom That Might Help with Chronic Fatigue
Chronic fatigue syndrome, or CFS, is a condition that doctors often can’t explain with lab tests. Patients describe an exhaustion that feels worse than the flu — but there’s no cure or reliable treatment. That’s why a supplement with roots in traditional Chinese medicine is being tested in a rigorous clinical trial.
Lingzhi, or Ganoderma lucidum, has been used for centuries in traditional medicine. Known as the “mushroom of immortality,” it has been used to treat everything from insomnia to cancer. But until now, there’s been little scientific evidence that it helps with chronic fatigue — or the fatigue that lingers after a severe case of COVID-19.
This study is testing a supplement called CP003, which contains a pharmacologically active extract of lingzhi. Researchers are looking to see if it improves physical and mental fatigue over a 6-week period — and whether it also affects sleep, anxiety, and depression.
What makes this study stand out is that it’s not only looking at whether the supplement works — it’s exploring why it might work. Scientists are examining how lingzhi affects inflammation, the immune system, and oxidative stress. These biological processes are known to contribute to fatigue, and if lingzhi is shown to influence them, it could open the door to new treatments for fatigue and other conditions involving chronic inflammation.
The Science Behind Lingzhi
Lingzhi is more than a mushroom — it’s a complex organism with a long history in traditional medicine. But until now, there has been little scientific evidence to support its use for chronic fatigue. That’s why this trial is important: it’s the first to systematically evaluate the efficacy and safety of lingzhi for chronic fatigue and post-COVID-19 fatigue.
The extract in CP003 contains compounds like triterpenes, polysaccharides, and other bioactive substances. These are believed to have anti-inflammatory and immunomodulatory effects — properties that may help reduce oxidative stress, a known contributor to fatigue.
What’s unusual about this study is its approach. Most clinical trials focus on whether a treatment works — not why it might. But by looking at biomarkers related to inflammation and the immune system, the researchers are aiming to uncover the biological pathways through which lingzhi might help people with chronic fatigue.
The Trial Design: A Waitlist-Controlled Approach
The study uses a randomized, waitlist-controlled trial design. Participants are randomly assigned to either the intervention group, which receives CP003 for 6 weeks, or a control group, which receives the supplement after the trial is complete. This helps researchers compare the effects of the supplement over time, while accounting for the placebo effect and natural symptom fluctuations.
The study is also designed to be methodologically rigorous. Data will be collected using REDCap, a secure electronic data capture system. Statistical analysis will use an intention-to-treat approach with inverse probability weighting for missing data, ensuring that even if some participants drop out, the results remain as accurate as possible.
The primary analysis will use generalized linear regression, adjusted for covariates and interaction terms, with results reported as mean differences and 95% confidence intervals. A P-value of less than .05 will be considered statistically significant.
This level of detail is important — it ensures that the results are reliable and can be generalized to a larger population. It also addresses the limitations of many previous studies on lingzhi, which have often lacked methodological rigor.
What This Trial Won’t Prove — And Why That Matters
Despite the promise of this study, it’s important to remember what it won’t prove. First, the data hasn’t been analyzed yet. The study is scheduled to complete its 12-week follow-up in mid-2026, and results are expected to be published in the same timeframe. That means we don’t yet know whether CP003 works, how it works, or if it’s safe.
Another limitation is that the study is focused on a specific population — people in Hong Kong with chronic fatigue or post-COVID-19 fatigue. While this is a significant and relevant group, the results may not be generalizable to other populations. The researchers are taking steps to ensure the sample is representative, but the study is limited to one location and involves only 130 participants.
The study is also looking at a wide range of outcomes, including physical and mental fatigue, sleep quality, anxiety, depression, and biomarkers related to inflammation and oxidative stress. While this approach is thorough, it also means the study is asking a lot of questions. The researchers will need to be careful not to overinterpret or draw unsupported conclusions.
Finally, the study is evaluating the safety of CP003. While safety is important, it’s not the same as proving the supplement is effective. The researchers will look for any adverse effects, but the absence of such effects doesn’t mean the supplement is beneficial. Safety and efficacy are two separate questions, and this study is focused on the latter.
Frequently Asked Questions
Q: What is CP003, and how is it made?
A: CP003 is a supplement containing a pharmacologically active extract of Ganoderma lucidum, a type of basidiomycete mushroom. The extract is believed to contain compounds like triterpenes and polysaccharides, which are thought to have anti-inflammatory and immunomodulatory effects.
Q: How long will the study last?
A: The study will last 12 weeks, with the intervention period spanning 6 weeks and a 6-week follow-up phase to assess the sustained effects.
Q: Will the results be published?
A: Yes, the researchers expect to submit the results for publication in mid-2026, after the completion of the 12-week follow-up for all participants.
Q: Is the study safe?
A: Safety will be a key focus of the study. The researchers will assess and report any adverse effects or side effects associated with CP003.
Q: Who is eligible to participate?
A: The study will enroll 130 participants in Hong Kong who have chronic fatigue syndrome or post-COVID-19 fatigue. The researchers are aiming for a representative sample of this population.
Sources
- ¶Effectiveness and Safety of a Supplement Containing a Pharmacologically Active Basidiomycete Mushroom for Chronic Fatigue and Post-COVID-19 Fatigue Syndrome: Protocol for a Randomized Controlled Trial
- ¶ClinicalTrials.gov NCT06739720
- ¶International registered report identifier (irrid) PRR1-10.2196/82633
Educational Disclaimer
This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.
We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.
If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.
Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.